Overview of pathophysiology of thrombotic thrombocytopenic purpura
PLASMIC score for diagnostic support of thrombotic thrombocytopenic purpura
Sukumar S, et al. Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. J Clin Med 2021; 10:536. doi: 10.3390/jcm10030536
Little DJ, et al. Long-term kidney outcomes in patients with acquired thrombotic thrombocytopenic purpura. Kidney Int Rep 2017; 2:1088–1095. doi: 10.1016/j.ekir.2017.06.007
Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18:2486–2495. doi: 10.1111/jth.15006
Zheng XL, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18:2496–2502. doi: 10.1111/jth.15010
Bendapudi PK, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study. Lancet Haematol 2017; 4:e157-e164. doi: 10.1016/S2352-3026(17)30026-1
Wynick C, et al. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada. Thromb Res 2020; 196:335–339. doi: 10.1016/j.thromres.2020.09.012
Scully M, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380:335–346. doi: 10.1056/NEJMoa1806311
Goshua G, et al. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021; 137:969–976. doi: 10.1182/blood.2020006052